A 28-year-old woman from rural Rajasthan presents with acute onset fever, severe throat pain, and dysphagia. Throat culture grows beta-hemolytic cocci in chains. Which finding on the organism best distinguishes Streptococcus pyogenes from Streptococcus agalactiae (Group B Streptococcus)?

## Distinguishing S. pyogenes from S. agalactiae ### Biochemical and Serological Identification Both organisms are beta-hemolytic streptococci, but they differ in Lancefield grouping, virulence factors, and biochemical properties. ### Comparison Table | Feature | S. pyogenes (GAS) | S. agalactiae (GBS) | |---------|-------------------|---------------------| | **Lancefield group** | **Group A** | **Group B** | | **Hyaluronic acid capsule** | **Yes (mimics host)** | No | | **Bacitracin sensitivity** | **Sensitive** | Resistant | | **CAMP test** | Negative | **Positive** | | **PYR test** | **Positive** | Negative | | **Hemolysis** | Beta | Beta | | **Habitat** | Pharynx, skin | Vagina, GI tract | ### Why Option A is Correct **Option A — Bacitracin susceptibility and hyaluronic acid capsule** — correctly identifies two features that are characteristic of *S. pyogenes* (Group A Strep) and **not** shared by *S. agalactiae* (Group B Strep): 1. **Bacitracin susceptibility**: S. pyogenes is sensitive to bacitracin (0.04 U disc), producing a zone of inhibition. S. agalactiae is **resistant** to bacitracin. This is a classic, rapid laboratory discriminator (Ananthanarayan & Paniker, Textbook of Microbiology). 2. **Hyaluronic acid capsule**: S. pyogenes possesses a hyaluronic acid capsule that mimics host connective tissue, enabling immune evasion. S. agalactiae does **not** have a hyaluronic acid capsule (it has a polysaccharide capsule of a different composition). Together, these two features uniquely characterize S. pyogenes and distinguish it from S. agalactiae. ### Why Option C is Incorrect Option C states "Lancefield grouping with group A antigen **and** hyaluronic acid capsule." While both features are indeed present in S. pyogenes, the **Lancefield group A antigen alone** is the definitive serological marker — it is not typically combined with capsule typing as a "distinguishing pair" in standard microbiology practice. More importantly, the **hyaluronic acid capsule is not unique to S. pyogenes as a distinguishing test** in the same practical sense as bacitracin susceptibility. The Lancefield grouping alone (group A vs. group B) is the gold-standard serological discriminator, but Option A provides the more operationally useful and classically tested combination of features. ### Why Other Options are Incorrect - **Option B (CAMP test positivity and resistance to bacitracin)**: These are features of *S. agalactiae* (GBS), not S. pyogenes. This option describes the wrong organism. - **Option D (Bile solubility and optochin susceptibility)**: These are features of *S. pneumoniae*, not streptococci in the pyogenes/agalactiae comparison. **Key Point:** The **bacitracin sensitivity test** (A disc) is the classic, rapid, and high-yield laboratory method to distinguish S. pyogenes (sensitive) from S. agalactiae (resistant). Combined with the presence of a hyaluronic acid capsule (unique to GAS), Option A is the best discriminator. **Clinical Pearl:** S. pyogenes causes acute pharyngitis, impetigo, scarlet fever, and post-streptococcal sequelae (rheumatic fever, PSGN). S. agalactiae causes neonatal meningitis and sepsis (vertical transmission during delivery) and UTIs in pregnant women. **High-Yield:** Mnemonic — "**A**-disc for **A**-strep (Group A = bacitracin **A**ctive/sensitive)."